- Report
- May 2026
- 150 Pages
Global
From €2416EUR$2,699USD£2,074GBP
- Report
- July 2026
- 160 Pages
Global
From €3715EUR$4,150USD£3,190GBP
- Report
- October 2025
- 160 Pages
Global
From €2829EUR$3,160USD£2,429GBP
€3536EUR$3,950USD£3,036GBP
- Report
- February 2026
- 150 Pages
Global
From €4342EUR$4,850USD£3,728GBP
- Report
- September 2025
- 150 Pages
Global
From €4342EUR$4,850USD£3,728GBP
- Report
- May 2018
- 204 Pages
Global
From €2103EUR$2,349USD£1,805GBP
- Report
- July 2023
- 115 Pages
Global
From €3447EUR$3,850USD£2,959GBP
- Report
- January 2025
- 100 Pages
Global
From €5327EUR$5,950USD£4,573GBP
- Report
- August 2025
- 191 Pages
Global
From €3174EUR$3,545USD£2,725GBP
€3526EUR$3,939USD£3,027GBP
- Report
- August 2025
- 185 Pages
Global
From €3174EUR$3,545USD£2,725GBP
€3526EUR$3,939USD£3,027GBP
- Report
- August 2025
- 187 Pages
Global
From €3174EUR$3,545USD£2,725GBP
€3526EUR$3,939USD£3,027GBP
- Report
- August 2025
- 189 Pages
Global
From €3174EUR$3,545USD£2,725GBP
€3526EUR$3,939USD£3,027GBP
- Report
- August 2025
- 189 Pages
Global
From €3174EUR$3,545USD£2,725GBP
€3526EUR$3,939USD£3,027GBP
- Report
- August 2025
- 198 Pages
Global
From €3174EUR$3,545USD£2,725GBP
€3526EUR$3,939USD£3,027GBP
- Report
- August 2025
- 190 Pages
Global
From €3174EUR$3,545USD£2,725GBP
€3526EUR$3,939USD£3,027GBP
- Report
- August 2025
- 192 Pages
Global
From €3174EUR$3,545USD£2,725GBP
€3526EUR$3,939USD£3,027GBP
- Report
- August 2025
- 196 Pages
Global
From €3174EUR$3,545USD£2,725GBP
€3526EUR$3,939USD£3,027GBP
From €4387EUR$4,900USD£3,766GBP
- Report
- October 2024
- 200 Pages
Global
From €3357EUR$3,750USD£2,882GBP
- Report
- May 2024
- 200 Pages
Global
From €3715EUR$4,150USD£3,190GBP

Levodopa is a drug used to treat Parkinson's disease, a neurological disorder that affects movement. It is a dopamine precursor, meaning it is converted into dopamine in the brain, which helps to reduce the symptoms of Parkinson's. Levodopa is usually taken in combination with other drugs, such as carbidopa, to increase its effectiveness. It is one of the most commonly prescribed drugs for Parkinson's, and is often the first line of treatment.
Levodopa is a part of the larger Central Nervous System (CNS) drug market, which includes drugs used to treat a variety of neurological disorders. The CNS drug market is highly competitive, with many different companies offering various treatments.
Some of the companies in the Levodopa market include Merck, Novartis, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more